Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for cancer. In collaboration with Servier, Allogene is developing UCART19, ALLO-501 and ALLO-501A, which are CAR T cell product candidates targeting CD19.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
